Abstract library

42 results for "ileum".
#326 Long-term Survival and Quality of Life in Patients with Ileum NET: A Single Center Experience
Introduction: Neuroendocrine tumors of the small bowel can be differentiated in terms of progression, survival time and health-related quality of life from endothelial tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Anne Reincke
Authors: Reincke A, Zahn S, Hornung H, Jauch K W, ...
#964 Ewing Sarcoma a Dangerous Pitfall for Poorly Differentiated Neuroendocrine Carcinoma (PDEC) in Ileum
Introduction: Ewing sarcoma (ES) primary to the ileum (IES) has rarely been documented, and shows close similarities in histology and clinical presentation with PDEC.EWSR1-FEV translocation is exceedingly rare in ES, as FEV expression is restricted to prostate, brain, and serotonin neuroendocrine cells (NE) and related tumors.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
#554 Analysis of the AJCC/ENETS Staging Classification for Midgut Neuroendocrine Tumors
Introduction: The American Joint Committee on Cancer (AJCC) and ENETS have independently introduced a novel TNM staging classification for jejunal-ileal NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Max Feldman
#942 Ileal Neuroendocrine Well-Differentiated Tumors: Prognostic factors with Focus on Loss of Succinate Dehydrogenase (SDHB) Expression
Introduction: Ileal Neuroendocrine Well-Differentiated Tumors (INWDT) are the most common neuroendocrine neoplasms in the gastrointestinal tract. Gene mutations of SDH complex drive pathogenesis of cancer cells through their role in angiogenesis and cell proliferation.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill
#876 Incidence and Prevalence of Neuroendocrine Tumors (NETs) of the Ileum and Colon (Excluding Appendiceal NETs) in Northern Ireland (NI) Over a 25-Year-Period (1988-2012)
Introduction: Incidence of NETs is quoted to be 2/100,000 with approximately 25% being tumors of the midgut, (0.5/100,000). Incidence is increasing. However, this may be in part due to improved diagnosis but it is also thought to be a true increase.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Professor Joy E Ardill
Keywords: MGC
#1139 Role of Enteroclysis MDTC in the Diagnosis and Follow-Up of Ileal Neuroendocrine Tumors
Introduction: Among all the well differentiated neuroendocrine tumors (NET) those originating from ileum present the more relevant diagnostic difficulties and remain therefore occult in a relevant percentage of cases in all the stages
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Daniele Maiettini
#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis
Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Simron Singh
#81 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): our experience in a multidisciplinary team in a university hospital
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a low incidence and prevalence representing < 2% of all gastrointestinal tumors with a heterogeneous biological behavior and an often complex management.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jose Manuel Cabezas-Agricola
#87 Alterations of E-cadherin, beta-catenin and caveolin-1 expression in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NETs) comprise a heterogeneous group of neoplasm with different histological patterns and biological behavior. Only limited information is available on immunohistochemical prognostic factors of disease. Alterations in the cell-cell adhesion system are closely associated with cell invasion and metastasis in many malignancies, including those of endocrine origin. Abnormal expression of E-cadherin and beta-catenin has been reported to play an important role in these processes. Caveolin-1 has recently been identified as a tumor metastasis modifier factor, which might increase the cell metastasis potential through the interaction with E-cadherin. However, the role of caveolin-1 in GEP NETs cell invasion remains unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Vera V Delektorskaya
Authors: Delektorskaya V, Chemeris G, ...